Tryptamine Therapeutics (ASX:TYP) launched patient recruitment for its clinical trial testing TRP-8803 combined with psychotherapy to potentially treat binge eating disorder (BED), according to a Monday Australian bourse filing.

The trial will enroll 12 BED patients in two groups of six, with each patient receiving two doses of TRP-8803 spaced 14 days apart following preparatory psychotherapy, the filing said. The first group will receive a mid-range dose, and the second group a high-range dose.

Recruitment started after completing key activities such as obtaining governance approval, submitting permits, finalizing patient cohort protocols, hiring staff, preparing patient-focused materials, and scheduling TRP-8803 manufacturing for the study, the filing added.

First dosing is scheduled for this quarter, with results expected by the fourth quarter, per the filing.

Tryptamine Therapeutics' shares jumped 3% in recent Monday trade.